New England Journal of Medicine· 2013Q1

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto et al.

3,410citations
Q1SCImago
2013year

Short summary

Crizotinib significantly improved progression-free survival (7.7 vs. 3.0 months) and response rates (65% vs. 20%) compared to standard chemotherapy in patients with previously treated, advanced ALK-positive non-small-cell lung cancer.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine